693823-79-9Relevant academic research and scientific papers
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition
Mihalic, Jeffrey T.,Fan, Pingchen,Chen, Xi,Chen, Xiaoqi,Fu, Ying,Motani, Alykhan,Liang, Lingming,Lindstrom, Michelle,Tang, Liang,Chen, Jin-Long,Jaen, Juan,Dai, Kang,Li, Leping
scheme or table, p. 3781 - 3785 (2012/07/27)
An initial SAR study resulted in the identification of the novel, potent MCHR1 antagonist 2. After further profiling, compound 2 was discovered to be a potent inhibitor of the hERG potassium channel, which prevented its further development. Additional opt
Stereoselective synthesis of a MCHr1 antagonist
Andersen, Denise,Storz, Thomas,Liu, Pingli,Wang, Xin,Li, Leping,Fan, Pingchen,Chen, Xiaoqi,Allgeier, Alan,Burgos, Alain,Tedrow, Jason,Baum, Jean,Chen, Ying,Crockett, Rich,Huang, Liang,Syed, Rashid,Larsen, Robert D.,Martinelli, Mike
, p. 9648 - 9655 (2008/03/17)
(Chemical Equation Presented) Melanin-concentrating hormone (MCH) is implicated in the feeding behavior in mammals affording a potential target to control overeating in people. Compound 1 (AMG 076) has been identified as a potent MCHr1 antagonist for the
FUSED HETEROCYCLIC COMPOUNDS
-
Page 45, (2010/02/07)
Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
